A Randomized Trial of Punctuated Antiretroviral Therapy in Ugandan HIV-Seropositive Adults With Pulmonary Tuberculosis and CD41 T-Cell Counts of $350 cells/lL

Simple item page
dc.contributor.authorNanteza, M. W.
dc.contributor.authorMayanja-Kizza, H.
dc.contributor.authorMupere, E.
dc.contributor.authorMugyenyi, P.
dc.contributor.authorMugerwa, R. D.
dc.contributor.authorHavlir, D. V.
dc.date.accessioned2023-03-07T09:07:08Z
dc.date.available2023-03-07T09:07:08Z
dc.date.issued2011
dc.description.abstractOptimal treatment of human immunodeficiency virus (HIV)–associated tuberculosis in patients with high CD4+ T-cell counts is unknown. Suppression of viral replication during therapy for tuberculosis may block effects of immune activation on T cells and slow HIV disease progression. We conducted a randomized trial in 214 HIV-infected patients with active tuberculosis and CD4+ T-cell counts of ≥350 cells/μL to determine whether 6 months of antiretroviral therapy given during tuberculosis treatment would improve clinical outcomes. Subjects were randomized to receive 6 months of abacavir-lamivudine-zidovudine concurrent with tuberculosis therapy or delayed antiretroviral therapy. Endpoints were CD4+ T-cell counts of <250 cells/μL, AIDS, or death. Intervention and comparison arms had similar median CD4+ counts (517 and 534 cells/μL, respectively) and HIV RNA levels (4.6 and 4.7 log10 copies/μL, respectively). Viral suppression was achieved in 86% of patients allocated to intervention. Seventeen subjects (15.6%) in the intervention arm developed study outcome compared to 25 subjects (22.8%) in the comparison arm (P = .17). Grade 3 or 4 adverse events were less frequent in the intervention arm. By 2 months, 90% of subjects in both arms were culture-negative for tuberculosis.Short-term antiretroviral therapy during tuberculosis treatment in patients with CD4+ T-cell counts of >350 cells/μL was safe and associated with clinical benefits.en_US
dc.identifier.citationNanteza, M. W., Mayanja-Kizza, H., Charlebois, E., Srikantiah, P., Lin, R., Mupere, E., ... & Whalen, C. C. (2011). A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4+ T-cell counts of≥ 350 cells/μL. Journal of Infectious Diseases, 204(6), 884-892.https://doi.org/10.1093/infdis/jir503en_US
dc.identifier.issn1537-6613
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/8103
dc.language.isoenen_US
dc.publisherJournal of Infectious Diseasesen_US
dc.subjectacquired immunodeficiency syndromeen_US
dc.subjectpulmonary tuberculosisen_US
dc.subjectsurrogate endpointsen_US
dc.titleA Randomized Trial of Punctuated Antiretroviral Therapy in Ugandan HIV-Seropositive Adults With Pulmonary Tuberculosis and CD41 T-Cell Counts of $350 cells/lLen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
A Randomized Trial of Punctuated Antiretroviral Therapy in Ugandan HIV-Seropositive Adults With Pulmonary Tuberculosis and CD4+ T-Cell Counts of ≥350 cellsμL.pdf
Size:
413.6 KB
Format:
Adobe Portable Document Format
Description:
A Randomized Trial of Punctuated Antiretroviral Therapy in Ugandan HIV-Seropositive Adults With Pulmonary Tuberculosis and CD4+ T-Cell Counts of ≥350 cells/μL
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences